mtbvac
Vaccineexperimental
Clinical trial activity
8 trials · 19 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
7
Phase 3
1
Phase 4
0
Earliest trial started Jan 1, 2013 (NCT02013245)
Timeline
Indications
Mechanism of action
- Mycobacterium tuberculosisImmunity, active
Mycobacterium tuberculosis immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- mtbvac
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06997367 | Phase 2 | Mar 1, 2025 | Bharat Biotech International Limited |
| NCT06272812 | Phase 2 | Sep 30, 2024 | International AIDS Vaccine Initiative, University of Zaragoza |
| NCT05947890 | Phase 2 | Jan 15, 2024 | Africa Health Research Institute, Biofabri, S.L, HIV Vaccine Trials Network, National Institute of Allergy and Infectious Diseases (NIAID), South African Tuberculosis Vaccine Initiative (SATVI) |
| NCT04975178 | Phase 3 | Jul 31, 2022 | Biofabri, S.L, Biomedical Research Center EPLS, Institut Pasteur, Stellenbosch University, TuBerculosis Vaccine Initiative, University of Cape Town, University of Kwa-Zulu Natal, University of Zaragoza, Wits Health Consortium (Pty) Ltd |
| NCT03536117 | Phase 2 | Jul 31, 2018 | Biofabri, S.L, South African Tuberculosis Vaccine Initiative (SATVI), TuBerculosis Vaccine Initiative, University of Zaragoza |
| NCT02933281 | Phase 1/Phase 2 (Phase 2) | Aug 1, 2017 | Aeras, Biofabri, S.L, SATVI, South African Tuberculosis Vaccine Initiative (SATVI), TuBerculosis Vaccine Initiative, University of Zaragoza |
| NCT02729571 | Phase 1/Phase 2 (Phase 2) | Sep 1, 2015 | Biofabri, S.L, South African Tuberculosis Vaccine Initiative (SATVI), Triclinium Clinical Trial Project Management, TuBerculosis Vaccine Initiative, University of Zaragoza |
| NCT02013245 | Phase 1 | Jan 1, 2013 | Biofabri, S.L, TuBerculosis Vaccine Initiative, University of Lausanne, University of Zaragoza |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (19)
19 organizations
Page 1 / 1